Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28621

Enrollment

400

Registered

2020-02-02

Start date

2020-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Staphylococcus aureus bacteremia

Interventions

Participants will be randomized to stop antibiotic treatment after either 4 weeks (28 days) or 6 weeks (42 days).

Eligibility

Inclusion criteria

Inclusion criteria: Adults with methicillin-sensitive complicated SAB with satisfactory clinical response to initial treatment will be eligible for inclusion.

Exclusion criteria

Exclusion criteria: Patients with infected prosthetic material or pregnant/lactating will be excluded.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is a composite of all-cause mortality or bacteriologically confirmed disease relapse.	—

Secondary

Measure	Time frame
Secondary outcomes will include antibiotic-related toxicity, length of hospital admission, perceived quality of life and societal costs.	—

Contacts

Public ContactKim Sigaloff

Amsterdam UMC

k.sigaloff@amsterdamumc.nl+625716090

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)